A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (Other)

Overall Status

Recruiting

CT.gov ID

NCT05556200

Collaborator

(none)

Enrollment

Locations

Arm

Anticipated Duration (Months)

19.3

Patients Per Site

0.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a phase II, open-labeled, multi-centered, single-arm, investigator-initiated clinical trial of camrelizumab (an anti-PD-1 antibody) in combination with apatinib (a VEGFR2 TKI) for neoadjuvant treatment of patients with triple-negative breast cancer and >10% tumor-infiltrating lymphocytes (TILs) in baseline breast tumors. We will enroll 58 subjects (Simon's two stage design). The study is designed to evaluate the efficacy and safety of camrelizumab in combination with apatinib in the neoadjuvant treatment of TNBC with a high proportion of TILs.

Condition or Disease	Intervention/Treatment	Phase
Breast Cancer Triple-Negative Breast Cancer	Drug: Anti-PD-1 monoclonal antibody Drug: VEGFR2 Tyrosine Kinase Inhibitor	Phase 2

Detailed Description

This a phase II, open-labeled, multi-centered, single-arm, investigator-initiated clinical trial to assess the efficacy and safety of camrelizumab combination with apatinib in female patients age of 18 to 70 with TNBC, and baseline tumor-infiltrating lymphocytes > 10%. The number of patients to be included is 58 patients (Simon's two stage design). The primary objective is to assess the pCR. All enrolled patients will be treated with camrelizumab 200mg (iv. 3mg/kg for patient whose weight is below 50kg) on day 1 of each 21-day cycle, and apatinib 250mg daily (po, d1-d21).

Study Design

Study Type:

Interventional

Anticipated Enrollment :

58 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Anticipated Study Start Date :

Oct 1, 2022

Anticipated Primary Completion Date :

Sep 1, 2025

Anticipated Study Completion Date :

Sep 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Experiment Eligible patients enrolled receive camrelizumab 200 mg, iv, d1, every 21 days (3 mg/kg if weight <50 kg) in combination with apatinib 250 mg, po, qd for neoadjuvant treatment for 8 cycles. Patients evaluated after neoadjuvant therapy with pCR receive 9 cycles of postoperative adjuvant camrelizumab (200 mg, iv, or 3 mg/kg if weight <50 kg, d1,q3W) + apatinib (250 mg, po, qd). Patients with non-pCR after neoadjuvant therapy receive adjuvant chemotherapy of the physician's choice (TPC).	Drug: Anti-PD-1 monoclonal antibody Camrelizumab 200 mg, iv, d1, q3W (3 mg/kg if weight <50 kg) Other Names: Camrelizumab Drug: VEGFR2 Tyrosine Kinase Inhibitor Apatinib 250 mg, po, qd Other Names: Apatinib

Arm

Intervention/Treatment

Experimental: Experiment

Eligible patients enrolled receive camrelizumab 200 mg, iv, d1, every 21 days (3 mg/kg if weight <50 kg) in combination with apatinib 250 mg, po, qd for neoadjuvant treatment for 8 cycles. Patients evaluated after neoadjuvant therapy with pCR receive 9 cycles of postoperative adjuvant camrelizumab (200 mg, iv, or 3 mg/kg if weight <50 kg, d1,q3W) + apatinib (250 mg, po, qd). Patients with non-pCR after neoadjuvant therapy receive adjuvant chemotherapy of the physician's choice (TPC).

Drug: Anti-PD-1 monoclonal antibody

Camrelizumab 200 mg, iv, d1, q3W (3 mg/kg if weight <50 kg)

Other Names:

Camrelizumab

Drug: VEGFR2 Tyrosine Kinase Inhibitor

Apatinib 250 mg, po, qd

Other Names:

Apatinib

Outcome Measures

Primary Outcome Measures

Pathological Complete Remission (pCR) rate [After neoadjuvant study treatment and surgery, up to approximately 24-26 weeks]
pCR rate (ypT0/Tis ypN0) is defined as the percentage of participants without residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current American Joint Committee on Cancer (AJCC) staging criteria assessed by the local pathologist at the time of definitive surgery.

Secondary Outcome Measures

Objective Response Rate (ORR) [After neoadjuvant study treatment and surgery, up to approximately 24-26 weeks]
The propotion of subjects with CR or PR according to RECIST v1.1.
Breast Conservation Rate [Up to approximately 24-26 weeks]
The percentage of patients who undergo breast-conserving surgery after neo-adjuvant therapy.
Incidence of Treatment-Emergent Adverse Events [From the first drug administration to within 90 days for the last dose]
Adverse events/serious adverse events.
Event-Free Survival (EFS) [Up to approximately 8 years]
Event-free survival (EFS) defined as the time from recruitment until documented disease recurrence, progression, or death from any cause in all participants. EFS events covered under "disease recurrence" will include local, regional, or distant recurrence and contralateral breast cancer. Ipsilateral or contralateral in situ disease and second primary non-breast cancers will not be counted as EFS events.
Overall Survival (OS) [Up to approximately 8 years]
defined as the time from randomization to death due to any cause.
Frequencies of Biomarkers [Up to approximately 24-26 weeks]
Biomarkers (including tumor/stromal PD-L1, stromal PD-1, tumor-infiltrating lymphocytes and tumor-infiltrating B cells, eg).

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients sign the written informed consent.
Women aged 18-70.
Patients with histologically confirmed operable invasive breast cancer (T1cN1-2 or T2-4N0-2)［ER-negative(IHC<1%), PR-negative(IHC<1%), HER2-negative（IHC-/+ or IHC++ and FISH/CISH-）］.
Percentage of tumor-infiltrating lymphocytes >10% in baseline breast tumor.
Patients with at least one measuring lesion that was conformed to RECIST v1.1 standard.
No previous breast cancer-related treatment, including chemotherapy, immunotherapy, endocrine therapy, radical surgery, or radiotherapy.
Patients can swallow pills.
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.
Patients with a life expectancy of at least 12 weeks.
The patient's blood test results prior to enrollment met the following criteria： • Hb≥90g/L; • Plt≥100^{9/L; • Serum albumin ≥3g/dL; • Neutrophils≥1.5}9/L;

• TSH≤ normal upper limit (ULN);

ALT and AST ≤1.5 ULN (liver metastases ≤3 ULN);
TBIL ≤ULN (total bilirubin ≤1.5 ULN in Gilbert's syndrome or liver metastasis subjects);
ALT and AST ≤1.5 ULN (liver metastases ≤3 ULN);
AKP≤ 2.5 ULN;
Renal function within 7 days before the first administration: serum creatinine ≤1.5 ULN or creatinine clearance ≥60mL/min.

Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose and must be willing to use very efficient barrier methods of contraception for the course of the study through 6 months after the last dose of study treatment.

Exclusion Criteria:

Combination of other malignancies or previous malignancies other than breast cancer within the last 5 years, except for basal cell carcinoma or flat cell carcinoma of the skin or carcinoma in situ of the uterine cervix that has been adequately controlled by treatment.
Those who are not suitable for immunotherapy in combination with active infection.
The combination of severe non-malignant disease that would affect patient compliance or put the patient at risk.
Concomitant with other antineoplastic therapy or are participating in other clinical trials.
Male breast cancer, bilateral breast cancer or inflammatory breast cancer.
Patients with dementia, mental abnormality or any mental illness that prevents understanding of the informed consent form.
Patients with history of allergic reaction or contraindication to the use of any drug component of this trial.
Patients with any active autoimmune disease or a history of autoimmune disease (e.g., the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enterocolitis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism; subjects with vitiligo or whose asthma has completely resolved in childhood and does not require any intervention in adulthood may be included; (Patients with asthma that requires medical intervention with bronchodilators cannot be included).
Have cardiac clinical symptoms or disease that are not well controlled, such as:

(1) NYHA class 2 or higher heart failure; (2) Unstable angina pectoris; (3) Myocardial infarction within 1 year; (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention.

Urine routine suggestive of urine protein ≥++, or confirmed 24-hour urine protein amount ≥1.0g.
Known presence of hereditary or acquired bleeding and thrombotic tendencies (e.g., hemophiliacs, coagulation disorders, thrombocytopenia, hypersplenism, etc.).
Patients with congenital or acquired immune deficiencies (e.g., HIV-infected individuals).
Live vaccines administered less than 4 weeks prior to study drug administration or possibly during the study.
Active tuberculosis. 15. Patients have received oral or intravenous antibiotic therapy within 2 weeks prior to neoadjuvant therapy.
Major surgical procedure within 4 weeks prior to the start of study treatment or anticipated need for major surgical procedure during the course of the study.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Guangzhou	Guangdong	China	510120
2	The First Affiliated Hospital of Nanjing Medical University	Nanjing	Jiangsu	China	210029
3	Second Military Medical University	Shanghai	Shanghai	China	200433